Samuel P. Niles

Samuel’s recent experience includes advising:

Public Offerings

• Metsera on its US$275 million IPO of common stock and subsequent follow-on public offering
• The underwriters on Aerovate Therapeutics’ US$140 million IPO of common stock
• Aziyo Biologics on its US$50 million IPO of Class A and Class B common stock
• Lyra Therapeutics on its US$60 million IPO of common stock
• Homology Medicines on its US$166 million IPO of common stock and follow-on offerings of common stock
• The underwriters on Rubius Therapeutics’ US$275 million IPO and US$200 million follow-on public offering of common stock
• The underwriters on Kaleido Biosciences’ US$75 million IPO of common stock and subsequent follow-on public offerings
• The underwriters on resTORbio’s US$98 million IPO of common stock
• Ra Pharma on its US$150 million follow-on public offering of common stock
• ContraFect on its US$52 million IPO of common stock and warrants to purchase common stock, as well as concurrent private placement of common stock and warrants to purchase common stock
• The underwriter on Collegium Pharmaceutical’s US$125 million registered public offering of senior convertible notes
• The underwriters on Blueprint Medicines’ US$345 million follow-on public offering of common stock
• The underwriter on Akebia Therapeutics’ US$89 million follow-on public offering of common stock
• The underwriters on Clearside Biomedical’s US$85 million follow-on public offering of common stock

Alternative Financing Transactions

• Everest Consolidator on its US$172 million SPAC IPO of units
• Aziyo Biologics on its US$14 million PIPE financing
• Lyra Therapeutics on its US$100 million PIPE financing
• Rafael Holdings on its US$104 million PIPE financing
• The sales agent on Neptune Wellness’ US$50 million at-the-market program of common stock under the US-Canadian multijurisdictional disclosure system
• Ally Bridge Group affiliates on multiple venture capital, PIPE, and other alternative investments
• Mallinckrodt on securities matters relating to its chapter 11 bankruptcy proceedings

Emerging Company Matters

• Akebia Therapeutics in its US$55 million term loan facility
• Indigo Agriculture on its US$535 million Series F financing and on prior investment rounds
• Dewpoint Therapeutics on its US$150 million Series C financing, prior investment rounds, and formation and general corporate matters
• Kojin Therapeutics on its US$60 million Series A financing, as well as formation and general corporate matters
• KSQ Therapeutics on its US$80 million Series C financing, prior investment rounds, and general corporate matters
• Biothea Pharma on its Series A financing
• CIBO Technologies on its US$30 million Series C financing, prior investment rounds, and general corporate matters
• Jnana Therapeutics on its US$50 million Series B financing and general corporate matters
• Ring Therapeutics on its US$117 million Series B financing and general corporate matters
• Cellarity on its US$123 million Series B financing and general corporate matters
• Atea Pharmaceuticals on its US$215 million Series D financing
• Centrexion Therapeutics on its US$67 million Series D financing and general corporate matters
• VistaJet on its US$600 million equity investment from a consortium of investors led by RRJ Capital